FDA grants additional Fast Track designation to Phanes’ spevatamig for first-line metastatic pancreatic cancer

The designation expands spevatamig’s regulatory support to the broader first-line metastatic pancreatic ductal adenocarcinoma population as Phanes advances its CLDN18.2 × CD47 bispecific antibody through Phase II development.

The US Food and Drug Administration (FDA) has granted Fast Track designation to Phanes Therapeutics’ spevatamig (PT886) in combination with chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma (PDAC), expanding on a previous Fast Track designation covering metastatic CLDN18.2-positive pancreatic adenocarcinoma.

The designation provides Phanes with opportunities for more frequent FDA interaction as it advances the Phase II TWINPEAK programme, but does not constitute regulatory approval or establish the therapy’s efficacy.

Field	Content
Alert Type	Industry Update
Topic	FDA Fast Track designation; clinical development
Organisation(s)	Phanes Therapeutics; US Food and Drug Administration (FDA)
Affected Stakeholders	Pancreatic cancer researchers; oncologists; clinical investigators; patients with metastatic pancreatic ductal adenocarcinoma
Therapy Area(s)	Oncology; Pancreatic cancer
Geography	United States
What Happened	The FDA has granted Fast Track designation to spevatamig (PT886) in combination with chemotherapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma. Spevatamig is Phanes Therapeutics’ investigational bispecific antibody targeting CLDN18.2 and CD47 and is being evaluated in the Phase I/II TWINPEAK study. The new designation is broader than the Fast Track designation granted in 2024 for metastatic CLDN18.2-positive pancreatic adenocarcinoma, removing the biomarker-positive qualification from the designated first-line population. Fast Track status can facilitate more frequent FDA interactions and potentially rolling review if applicable regulatory requirements are subsequently met; it does not represent approval. (BIO International Convention 2026)
Why It Matters	The broader designation is relevant because Phanes is developing spevatamig as a potential first-line treatment without restricting enrolment to a narrowly defined CLDN18.2-positive population. Pancreatic ductal adenocarcinoma remains difficult to treat, and the regulatory designation could support closer interaction with the FDA as Phanes determines the programme’s path towards pivotal development. Clinical benefit, however, still needs to be established in prospective trials.
Supporting Context	Spevatamig is a native IgG-like CLDN18.2 × CD47 bispecific antibody designed to enhance innate immune activity. In previously reported Phase II data from first-line metastatic PDAC, Phanes reported a 40% objective response rate and 93% disease control rate among 15 patients receiving the 2 mg/kg dose with gemcitabine and nab-paclitaxel, with median progression-free survival of 7.3 months; these early findings come from a small, non-randomised cohort and require further confirmation. (Phanes Therapeutics, Inc)
Who Is Most Affected	Phanes and investigators developing spevatamig are most directly affected because the designation provides a mechanism for increased FDA interaction as the programme advances. Patients with metastatic PDAC are the relevant clinical population, although spevatamig remains investigational and is not currently an approved treatment.
Industry Impact	The designation supports continued late-stage planning for a differentiated immunotherapy approach in pancreatic cancer based on simultaneous CLDN18.2 and CD47 targeting. Phanes completed enrolment in its Phase II first-line metastatic PDAC study in June 2026 and expects topline results by the end of 2026. (PR Newswire)
Key Takeaway	The additional Fast Track designation broadens FDA regulatory support for spevatamig as Phanes evaluates whether its CLDN18.2 × CD47 approach can progress towards pivotal development in first-line metastatic pancreatic cancer.
What to Watch	Topline Phase II results expected by the end of 2026 will be the principal next clinical milestone, particularly whether efficacy and safety findings support Phanes’ plans to move spevatamig towards Phase III development. (PR Newswire)
Primary Source	Phanes Therapeutics
Relevant Date	17 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com